Google DeepMind

Google’s leadership announcement combines two large changes: Demis Hassabis is becoming chair of Google DeepMind, while Jeff Dean, Sanjay Ghemawat, Oriol Vinyals, and Quoc Le will build Discovery Loop outside Google. Google remains an investor and cloud provider.

HN readers treated the personnel move as the headline, but the sharper question was institutional: how much of Google’s AI research culture is leaving with a group that says it wants to automate scientific and engineering discovery?

One reader tallied roughly twenty philosophers across every lab on earth, against thousands of engineers, and reckoned there are more economists than philosophers on the payroll. Another noted Starbucks employs orders of magnitude more philosophy graduates than all the labs combined.

Two reads of the actual job surfaced: 'hired to launder regulatory capture for a trillion-dollar corporation,' versus a Fortune 500 senior engineer who holds only a BA in philosophy and calls it the most underrated degree he owns.

J-space is tiny: it holds only a few dozen concepts at once and accounts for under a tenth of the model's activity, with most processing routing around it. Yet Claude can report, and even nudge, what sits inside.

One reader deflated the mystique, reading J-space as a shared abstract-reasoning subspace, not a mind.

Google shipped Nano Banana 2 Lite, a distilled Gemini image model that renders in seconds at $0.034 an image. An early tester confirmed it behaves like a lighter Nano Banana 2 with good text rendering, but you can't force aspect ratios like the full model.

Two things the thread caught: the comparison chart quietly omits ChatGPT and DALL-E, and one longtime engineer noted Grok's image model beats Nano Banana on nearly every metric Google chose to highlight.

Two senior names left Google DeepMind in two days: Noam Shazeer, then Jumper. The thread treated it less as one departure than as a pattern, and started guessing what is going wrong inside Google.

One read tied the move to Anthropic's recent purchase of a biotech outfit and a bet on using AI to discover drugs. A skeptic countered that the whole industry is now a revolving door priced around the next IPO.